Medico Remedies Ltd
MEDICO NSE
Medico Remedies Ltd
HealthcareNSE: MEDICO BSE: 540937 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹376 Cr
Volatility
Moderate
P/E Ratio
28.46
EBITDA
₹17.03 Cr
Return on Equity
16.16%
Debt to Equity
0.25
Book Value
₹9.1
52W High
₹56.88
52W Low
₹30.22
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Medico Remedies Ltd insights
33 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is expected to give good quarter
- Company has delivered good profit growth of 38.3% CAGR over last 5 years
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 11.0% over past five years.
- Earnings include an other income of Rs.5.93 Cr.
- Promoter holding has decreased over last 3 years: -12.0%
Growth Rate
Revenue Growth
34.36% ↗
Net Income Growth
28.71% ↘
Cash Flow Change
100.41% ↗
ROE
2.08% ↗
ROCE
2.41% ↗
EBITDA Margin (Avg.)
-30.38% ↘
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.99 | 31.47 | 42.36 | 29.77 | 41.32 | 30.8 | 39.35 | 39.49 | 41.3 | 38.25 | 52.64 | 58.68 | 56.81 |
| Expenses | 24.82 | 29.01 | 39.29 | 27.04 | 36.67 | 27.98 | 36.94 | 36.38 | 34.64 | 35.43 | 49.91 | 54.35 | 49.66 |
| Operating Profit | 3.17 | 2.46 | 3.07 | 2.73 | 4.65 | 2.82 | 2.41 | 3.11 | 6.66 | 2.82 | 2.73 | 4.33 | 7.15 |
| OPM % | 11.33% | 7.82% | 7.25% | 9.17% | 11.25% | 9.16% | 6.12% | 7.88% | 16.13% | 7.37% | 5.19% | 7.38% | 12.59% |
| Other Income | 0.04 | 0.31 | 0.96 | 0.27 | 0.58 | 0.29 | 0.68 | 1.43 | 0.29 | 0.66 | 1.72 | 0.68 | 2.87 |
| Interest | 0.21 | 0.17 | 0.18 | 0.22 | 0.25 | 0.18 | 0.21 | 0.28 | 0.49 | 0.28 | 0.24 | 0.39 | 0.9 |
| Depreciation | 0.73 | 0.71 | 0.71 | 0.72 | 0.74 | 0.75 | 0.75 | 0.76 | 0.77 | 0.77 | 0.73 | 0.79 | 0.8 |
| PBT | 2.27 | 1.89 | 3.14 | 2.06 | 4.24 | 2.18 | 2.13 | 3.5 | 5.69 | 2.43 | 3.48 | 3.83 | 8.32 |
| Tax % | 22.47% | 29.63% | 22.61% | 30.1% | 26.89% | 27.06% | 27.23% | 25.14% | 23.9% | 25.51% | 25.86% | 25.07% | 29.69% |
| Net Profit | 1.77 | 1.32 | 2.43 | 1.45 | 3.1 | 1.58 | 1.55 | 2.62 | 4.34 | 1.82 | 2.57 | 2.87 | 5.86 |
| EPS in Rs | 0.21 | 0.16 | 0.29 | 0.17 | 0.37 | 0.19 | 0.19 | 0.32 | 0.52 | 0.22 | 0.31 | 0.35 | 0.71 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | 140 | 145 | 151 | 206 |
| Expenses | 48 | 63 | 50 | 58 | 95 | 86 | 117 | 114 | 131 | 132 | 136 | 189 |
| Operating Profit | 3 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 10 | 13 | 15 | 17 |
| OPM % | 6% | 5% | 7% | 6% | 2.8% | 3.2% | 4.3% | 6% | 7% | 9% | 10% | 8% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | 3 | 6 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| PBT | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 6 | 10 | 11 | 14 | 18 |
| Tax % | 28% | 40% | 4% | 35% | 28% | 26% | 30% | 26% | 28% | 27% | 25% | 27% |
| Net Profit | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 7 | 8 | 10 | 13 |
| EPS in Rs | 0.25 | 0.35 | 0.25 | 0.15 | 0.19 | 0.2 | 0.31 | 0.58 | 0.87 | 1 | 1.22 | 1.58 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 12 | 13 | 13 | 23 | 24 | 26 | 28 | 20 | 27 | 36 | 46 | 59 |
| Borrowings | 8 | 14 | 19 | 13 | 14 | 14 | 15 | 13 | 10 | 8 | 15 | 19 |
| Other Liabilities | 14 | 17 | 13 | 20 | 35 | 32 | 28 | 28 | 34 | 36 | 43 | 59 |
| Total Liabilities | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 96 | 120 | 153 |
| Fixed Assets | 8 | 7 | 7 | 7 | 12 | 13 | 15 | 18 | 22 | 21 | 21 | 20 |
| CWIP | 0 | 0 | 3 | 4 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 |
| Other Assets | 27 | 38 | 39 | 48 | 63 | 60 | 59 | 59 | 64 | 73 | 96 | 129 |
| Total Assets | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 96 | 120 | 153 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | — | -3 | 5 | 5 | 1 | -11 | 6 | 8 | 2 | 5 | 6 |
| Investing | — | — | -3 | -5 | -4 | -3 | -17 | -2 | -7 | -3 | -3 | -5 |
| Financing | — | — | 6 | -1 | -1 | 3 | 18 | -6 | -2 | 0 | -1 | -1 |
| Net Cash Flow | — | — | 0 | 0 | 0 | 0 | -10 | -2 | 0 | -1 | 1 | 1 |
| Free Cash Flow | — | — | -4 | 3 | 1 | -2 | -28 | 3 | 2 | 0 | 2 | 1 |
| CFO/OP | — | — | -68 | 162 | 198 | 53 | -198 | 104 | 111 | 43 | 58 | 64 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53 | 107 | 122 | 102 | 109 | 98 | 82 | 92 | 94 | 125 | 138 | 145 |
| Inventory Days | 76 | 63 | 96 | 125 | 74 | 99 | 58 | 76 | 69 | 54 | 90 | 72 |
| Days Payable | 122 | 106 | 112 | 147 | 149 | 143 | 100 | 113 | 108 | 105 | 117 | 119 |
| Cash Conversion Cycle | 6 | 64 | 105 | 80 | 33 | 54 | 39 | 54 | 54 | 75 | 111 | 98 |
| Working Capital Days | 21 | 53 | 110 | 88 | 49 | 61 | 50 | 52 | 54 | 74 | 90 | 87 |
| ROCE % | 10% | 11% | 10% | 9% | 8% | 8% | 10% | 15% | 21% | 21% | 21% | 23% |
Documents
1
Clarification sought from Medico Remedies Ltd
3 Aug - Exchange has sought clarification from Medico Remedies Ltd on August 3, 2026 with reference to significant movement in price, in order to ensure that investors … 3 Aug - Exchange has sought clarification from Medico Remedies Ltd on August 3, 2026 with reference to significant movement in price, in order to ensure that investors …
2
Intimation Of Action Taken Or Order Passed By Regulatory,
Statutory, Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations')
16 Apr - NSE and BSE levied Rs. 63,720 each for Regulation 6(1) non-compliance; waiver rejected, fines paid. 16 Apr - NSE and BSE levied Rs. 63,720 each for Regulation 6(1) non-compliance; waiver rejected, fines paid.
3
Board Meeting Outcome for Outcome Of Board Meeting
12 Feb - Board approved unaudited standalone results for quarter and half year ended 31 Dec 2025. 12 Feb - Board approved unaudited standalone results for quarter and half year ended 31 Dec 2025.
5
Announcement under Regulation 30 (LODR)-Change in Management
18 Feb - Board appointed Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer on 18 Feb 2026. 18 Feb - Board appointed Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer on 18 Feb 2026.
Frequently Asked Questions about Medico Remedies Ltd
What does Medico Remedies Ltd do?
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
Where is Medico Remedies Ltd (MEDICO) listed?
Medico Remedies Ltd is listed on the Indian stock exchanges. It is listed on NSE: MEDICO and BSE: 540937. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Medico Remedies Ltd belong to?
Medico Remedies Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Medico Remedies Ltd?
Medico Remedies Ltd has a market capitalisation of approximately ₹376.08 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Medico Remedies Ltd?
The Price-to-Earnings (PE) ratio of Medico Remedies Ltd is 28.46. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Medico Remedies Ltd?
Over the past 52 weeks, Medico Remedies Ltd has traded between a low of ₹30.22 and a high of ₹56.88. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Medico Remedies Ltd?
Medico Remedies Ltd has a Return on Equity (ROE) of 16.16%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Medico Remedies Ltd on Tapetide?
On Tapetide, you can view Medico Remedies Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
Website medicoremedies.com
CEO Mr. Haresh Kapurlal Mehta
Employees 213
Listed 2022-05-26
Face Value ₹ 2
Issued Size 8,29,84,000